Sunshine Heart to Present at the 27th Annual Piper Jaffray Healthcare Conference on December 2, 2015
November 25 2015 - 5:30AM
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that Chief
Financial Officer, Claudia Drayton, is scheduled to present at the
27th Annual Piper Jaffray Healthcare Conference in New York, NY on
December 2nd at 12:00 PM ET.
About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System, or C-Pulse System, an
investigational device in the United States, Canada and
countries that do not recognize the CE mark approval, utilizes the
scientific principles of intra-aortic balloon counter-pulsation
applied in an extra-aortic approach to assist the left ventricle by
reducing the workload required to pump blood throughout the body,
while increasing blood flow to the coronary arteries. Combined,
these potential benefits may help sustain the patient's current
condition or, in some cases, reverse the heart failure process,
thereby potentially preventing the need for later-stage heart
failure devices, such as left ventricular assist devices (LVADs),
artificial hearts or transplants. It may also provide relief from
the symptoms of Class III and ambulatory Class IV heart failure and
improve quality of life and cardiac function. Based on the results
from our feasibility study, we also believe that some patients
treated with our C-Pulse System may be able to stop using the
device due to sustained improvement in their conditions as a result
of the therapy.
Caution: Investigational device, limited by Federal
(or United States) Law to Investigational use.
About Sunshine® Heart
Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical
device company focused on developing, manufacturing and
commercializing the C-Pulse System for treatment of Class III and
ambulatory Class IV heart failure. Sunshine Heart has
completed an approved U.S. Food and Drug Administration (FDA)
feasibility clinical study of the C-Pulse System and presented the
results in November 2011. In March 2012,
the FDA notified the Company that it could move forward
with an investigational device exemption (IDE)
application. Sunshine Heart received unconditional
approval from the FDA in November 2012 to initiate
its pivotal study. In July 2012, Sunshine
Heart received CE Mark approval for its C-Pulse System
in Europe. Sunshine Heart is a
Delaware corporation headquartered
in Minneapolis with wholly owned subsidiaries
in Australia and Ireland. The Company has been
listed on the NASDAQ Capital Market since February
2012.
Forward-Looking Statements
Certain statements in this release are forward-looking
statements that are based on management's beliefs, assumptions,
expectations, and information currently available to management.
All statements that address future operating performance, events or
developments that we expect or anticipate will occur in the future
are forward-looking statements, including, without limitation, our
expectations with respect to future clinical study activities and
results including patient enrollment in studies. These
forward-looking statements are subject to numerous risks and
uncertainties, including, without limitation, the possibility that
our clinical studies do not meet their enrollment goals, meet their
endpoints or otherwise fail, that regulatory authorities do not
accept our application or approve the marketing of the C-Pulse
System, the possibility that we may be unable to raise the funds
necessary for the development and commercialization of our
products, that we may not be able to commercialize our products
successfully in the EU and the other risk factors described under
the caption "Risk Factors" and elsewhere in our filings with
the Securities and Exchange Commission. You should not place
undue reliance on forward-looking statements because they speak
only as of the date when made and may turn out to be inaccurate. We
do not assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. We may not actually achieve the plans,
projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ
materially from those disclosed in the forward-looking
statements.
CONTACT: For further information, please contact:
Investor:
Candice Knoll
Blueprint Life Science Group
T: +1-415-375-3340 Ext. 4
Claudia Drayton
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200
Media:
David Schull
Russo Partners
T: +1-212-845-4271
Christopher Hippolyte
Russo Partners
T: + 1-646-942-5634
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024